References
- KahnRSFleischhackerWWBoterHEffectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialLancet200837196181085109718374841
- LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
- Liu-SeifertHAdamsDHKinonBJDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Med200532116375765
- WeidenPJSwitching antipsychotics: an updated review with a focus on quetiapineJ Psychopharmacol200620110411816204323
- AlmondSKnappMFrancoisCToumiMBrughaTRelapse in schizophrenia: costs, clinical outcomes and quality of lifeBr J Psychiatry200418434635115056580
- LeslieDLRosenheckRAFrom conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medicationsAm J Psychiatry200215991534154012202274
- StroupTSLiebermanJAMcEvoyJPEffectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychoticAm J Psychiatry2006163461162216585435
- WeidenPJOlfsonMCost of relapse in schizophreniaSchizophr Bull19952134194297481573
- HensleyPLNurnbergHGFormulary restriction of selective serotonin reuptake inhibitors for depression: potential pitfallsPharmacoeconomics2001191097398211735668
- HeiläHIsometsäETHenrikssonMMHeikkinenMEMarttunenMJLönnqvistJKSuicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medicationJ Clin Psychiatry199960320020810192600
- LaderMWhat is relapse in schizophrenia?Int Clin Psychopharmacol19959Suppl 5597622834
- Fiscal Year 2001 National MSIS Tables (2004). [cited 2009 April 27] Available from: http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/02_MSISData.asp
- KronickRGilmerTDreyfusTImproving health-based payment for Medicaid beneficiaries: CDPSHealth Care Financ Rev2000213296411481767
- JärbrinkKKreifNBenedictAQuality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophreniaCurr Med Res Opin200925370971619196221
- GibsonPJDamlerRJacksonEAThe impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid populationValue Health200471223514720128
- GilmerTPDolderCRLacroJPAdherence to treatment with antip-sychotic medication and health care costs among Medicaid beneficiaries with schizophreniaAm J Psychiatry2004161469269915056516
- KnappMKingDPugnerKNon-adherence to antipsychotic medication regimens: associations with resource use and costsBr J Psychiatry200418450951615172945
- SvarstadBLShiremanTISweeneyJKUsing drug claims data to assess the relationship of medication adherence with hospitalization and costsPsychiatr Serv200152680581111376229
- YuAPBen-HamadiRBirnbaumHGComparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid populationCurr Med Res Opin200925375576419199435
- WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv200455888689115292538
- LawMRSoumeraiSBRoss-DegnanDAdamsASA longitudinal study of medication nonadherence and hospitalization risk in schizophreniaJ Clin Psychiatry2008691475318312037